A new combined-database cytogenetic risk stratification system (Haase D31).
| Risk Group . | Karyotypes (22 groups) . | Median survival, mos . | Time until 25% of patients developed AML, mo . |
|---|---|---|---|
| Derived by Haase D et al31 based on combined German-Austrian, Spanish MDS Registry, and IMRAW cohorts. Univariate analysis. | |||
| Favorable | 5q-, 12p-, 20q-, +21, -Y, 11q-, t(11(q23)), normal, any 2 abnormalities including 5q- | 51 | 71.9 |
| Intermediate-1 | +1q, 3q21/q26 abnormalities, +8, t(7q), +19, −21, any other single abnormality, any double abnormality not including abnormalities of chromosomes 5q or 7 | 29 | 16 |
| Intermediate-2 | -X, -7 or 7q-, any double abnormality with -7 or 7q-, complex with 3 abnormalities | 15.6 | 6 |
| Unfavorable | Complex with > 3 abnormalities | 5.9 | 2.8 |
| Risk Group . | Karyotypes (22 groups) . | Median survival, mos . | Time until 25% of patients developed AML, mo . |
|---|---|---|---|
| Derived by Haase D et al31 based on combined German-Austrian, Spanish MDS Registry, and IMRAW cohorts. Univariate analysis. | |||
| Favorable | 5q-, 12p-, 20q-, +21, -Y, 11q-, t(11(q23)), normal, any 2 abnormalities including 5q- | 51 | 71.9 |
| Intermediate-1 | +1q, 3q21/q26 abnormalities, +8, t(7q), +19, −21, any other single abnormality, any double abnormality not including abnormalities of chromosomes 5q or 7 | 29 | 16 |
| Intermediate-2 | -X, -7 or 7q-, any double abnormality with -7 or 7q-, complex with 3 abnormalities | 15.6 | 6 |
| Unfavorable | Complex with > 3 abnormalities | 5.9 | 2.8 |